BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
54.99
-0.18 (-0.33%)
At close: Jun 30, 2025, 4:00 PM
54.97
-0.02 (-0.04%)
After-hours: Jun 30, 2025, 4:00 PM EDT
BioMarin Pharmaceutical Employees
BioMarin Pharmaceutical had 3,040 employees as of December 31, 2024. The number of employees decreased by 361 or -10.61% compared to the previous year.
Employees
3,040
Change (1Y)
-361
Growth (1Y)
-10.61%
Revenue / Employee
$970,469
Profits / Employee
$172,330
Market Cap
10.55B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 3,040 | -361 | -10.61% |
Dec 31, 2023 | 3,401 | 319 | 10.35% |
Dec 31, 2022 | 3,082 | 37 | 1.22% |
Dec 31, 2021 | 3,045 | -14 | -0.46% |
Dec 31, 2020 | 3,059 | 58 | 1.93% |
Dec 31, 2019 | 3,001 | 152 | 5.34% |
Dec 31, 2018 | 2,849 | 268 | 10.38% |
Dec 31, 2017 | 2,581 | 288 | 12.56% |
Dec 31, 2016 | 2,293 | 135 | 6.26% |
Dec 31, 2015 | 2,158 | 477 | 28.38% |
Dec 31, 2014 | 1,681 | 340 | 25.35% |
Dec 31, 2013 | 1,341 | 252 | 23.14% |
Dec 31, 2012 | 1,089 | 87 | 8.68% |
Dec 31, 2011 | 1,002 | 131 | 15.04% |
Dec 31, 2010 | 871 | 151 | 20.97% |
Dec 31, 2009 | 720 | 71 | 10.94% |
Dec 31, 2008 | 649 | 124 | 23.62% |
Dec 31, 2007 | 525 | 115 | 28.05% |
Dec 31, 2006 | 410 | 96 | 30.57% |
Dec 31, 2005 | 314 | -45 | -12.53% |
Dec 31, 2004 | 359 | 87 | 31.99% |
Dec 31, 2003 | 272 | 53 | 24.20% |
Dec 31, 2002 | 219 | 3 | 1.39% |
Dec 31, 2001 | 216 | 42 | 24.14% |
Dec 31, 2000 | 174 | 25 | 16.78% |
Dec 31, 1999 | 149 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
BMRN News
- 6 days ago - BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress - PRNewsWire
- 5 weeks ago - INOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc. - INZY - Business Wire
- 6 weeks ago - BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma - PRNewsWire
- 7 weeks ago - BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings - PRNewsWire
- 2 months ago - BioMarin Pharmaceutical Inc. (BMRN) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance - PRNewsWire
- 2 months ago - BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET - PRNewsWire
- 3 months ago - BioMarin Pharmaceutical: Pegasus Success May Lead To Palynziq Label Expansion - Seeking Alpha